Professor Hua Yan, a renowned ophthalmologist from Tianjin Medical University General Hospital, has made a series of breakthroughs in the field of ocular trauma and vitreoretinal diseases.

Proliferative vitreoretinopathy (PVR) following ocular trauma has always been a major challenge in the field of ophthalmology, posing a serious threat to the visual recovery of patients after ocular trauma. Hua utilized a multi-omics research strategy to depict the epigenetic landscape of RPE cells in traumatic PVR, constructed a transcription factor regulatory network, and proposed multiple intraocular intervention measures that can effectively alleviate the progression of PVR. The results were recently published in the renowned journal Nature Communication.

In addition, Yan's researched age-related macular degeneration (AMD) utilized techniques such as flow cytometry and single-cell sequencing to analyze the role and mechanisms of NK cells in AMD, and proposed new treatment strategies for neovascular AMD. The results have been published in the renowned journal Science Translational Medicine.

As a world leader in the field of ophthalmology, professor Yan has dedicated himself to basic research on ocular trauma and vitreoretinal diseases for decades. He has also continually pioneered new treatment concepts and surgical techniques in clinical practice.

In the treatment of ocular trauma, he believes that no light perception in eyes after trauma is no longer an absolute indication for enucleation; he introduced the concept of intraocular exploration; advocated for the use of silicone oil tamponade to prevent retinal detachment after endophthalmitis operation; applied intravitreal triamcinolone acetonide (TA) to suppress traumatic PVR; and developed new technologies such as artificial intelligence systems to predict visual prognosis after ocular trauma, significantly improving treatment outcomes and preserving patients' eyes.

In the treatment of vitreoretinal diseases, he proposed perioperative management principles for patients with proliferative diabetic retinopathy (PDR) complicated by severe systemic diseases; advocated for the concept of integrating ophthalmic surgery for neovascular glaucoma; and discovered and confirmed a new hemostatic role of TA in PDR surgery, significantly improving treatment outcomes.

Yan has led the development of international guidelines, multiple expert consensuses, and national group standards. He has been awarded the First Prize in the Chinese Medical Science and Technology Award, as well as the Special Prize and First Prize in the Tianjin Science and Technology Progress Awards.

He has delivered keynote speeches at various global ophthalmology conferences, including the World Ophthalmology Congress, the American Association for Research in Vision and Ophthalmology (ARVO), and the Asia-Pacific Academy of Ophthalmology, promoting his latest technologies worldwide.

Due to his outstanding achievements in the field of ophthalmology, the China-Europe Science and Technology Cooperation Association recently established the China-Europe (Germany) Ophthalmic Research and Development Innovation Center in Germany and appointed Professor Yan as the Director of the Academic Committee and the Chief Scientist of this center.